Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

1 booster (and Moderna’s, though the TGA has not approved this one at ... Scientists keep updating the COVID vaccines in an effort to keep up with these changes. The better matched the vaccine “spike” ...

If you missed the early fall push for flu and COVID-19 vaccines, it’s not too late. Health officials say it’s important to get vaccinated ahead of the holidays, when respiratory bugs tend to spread ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

Shares of several of the world’s largest vaccine makers fell Friday, the day after Donald Trump announced he had selected ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...

As Louisiana’s rate of fully vaccinated children slips as part of blowback related to the COVID-19 pandemic, health care ...